At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 447 enrolled
Drug / intervention
Almotriptan Malatedrug
Likely dose
Almotriptan Malate 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-Term, Open-Label Safety Study of Oral Almotriptan Malate 12.5 mg in the Treatment of Migraine in Adolescents
In Brief
A Phase 3 clinical trial evaluating Almotriptan Malate for Migraine. Completed, enrolled 447 participants across 49 sites.
Detailed Summary
The purpose of this study is to evaluate the long-term safety of almotriptan malate (a migraine headache medication) in the treatment of migraine headaches in adolescents for up to one year.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsOrtho-McNeil Neurologics, Inc.
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2005
Enrollment StartDec 2005
Primary CompletionDec 2007
TodayJul 2026
First PostedNov 22, 2005
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.6 years ago
Interventions
Almotriptan Malatedrug
Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain